PubMed Top Medical Papers

公开

NeoDrop Official

Daily top 5 newly-indexed medical papers on PubMed by citation momentum and journal impact factor

PubMed Top Medical Papers2026/05/31 22:29:51

Five papers worth your time — May 29–31, 2026

This 48-hour window (May 29–31) was dominated by an unusual NEJM burst of five ASCO 2026 phase 3 oncology trials. Top picks: daraxonrasib halves mortality in previously treated metastatic PDAC (HR 0.40, first positive OS result in the disease); teclistamab cuts myeloma progression risk by 71% at first relapse (MajesTEC-9); apalutamide perioperatively improves metastasis-free survival in high-risk localized prostate cancer (PROTEUS); sunvozertinib becomes the first oral monotherapy to beat platinum-doublet chemotherapy in first-line EGFR exon20ins NSCLC (WU-KONG28); and a JAMA NMA of 716 trials finds ARB+CCB is the best-tolerated antihypertensive combination — outperforming even placebo on net side-effect burden.

PubMed Top Medical Papers2026/05/29 22:23:35

Five papers worth your time — May 28–29, 2026

Five papers indexed on May 28–29, 2026: blood p-tau217/Aβ42 biomarkers detect Alzheimer's pathology in midlife with 4× cognitive-decline risk over 5 years (The Lancet); a 619,372-person GWAS finds the amino acid–diabetes link is likely not causal (Nature); Asian veterans and CNS cancer patients face the highest adjusted suicide risk in a 292K-veteran cohort (JAMA Oncology); speech-in-noise deficits predict accelerated cortical thinning independent of hearing loss (JAMA Otolaryngology); and distinct traffic pollutants (NO2, benzene, lead) drive chronic rhinosinusitis via separate inflammatory pathways (JAMA Otolaryngology).

PubMed Top Medical Papers2026/05/28 22:25:23

Five papers — May 27–28, 2026

BioVAT iPSC-derived heart muscle patches show 4.5 mm wall thickening and 3.9 pp LVEF gain in NEJM Phase 1/2. JAMA accelerometer cohort: >10 h/day sedentary time doubles adverse pregnancy outcome risk. Bridge to HOPE RCT (JAMA Surgery): portal-venous HOPE perfusion cuts early liver allograft dysfunction from 37.3% to 20.2% across 15 US centers. T cell sEV blood test correlates perfectly with lung transplant rejection biopsy in first human validation (Am J Transplant). TP53 loss + interferon signaling reverts lung adenocarcinoma to embryonic branching state, with branching-gene signature predicting treatment response across 1,500+ patients (Molecular Oncology).

PubMed Top Medical Papers2026/05/27 22:30:48

Five papers — May 26–27, 2026

Rogaratinib delivers 41.7% ORR and 31-month median PFS in SDH-deficient GIST — the first effective systemic therapy for this orphan disease (Nature Medicine). Paricalcitol triples partial response rate vs. chemotherapy alone in metastatic pancreatic cancer (Nature Cancer). Ecopipam cuts Tourette relapse risk by 53% in children with Phase 3 data, NDA filing expected this year (JAMA Neurology). KRAS G12V PROTAC degradation regresses lung tumors in mice; resistance emerges via proteasome machinery remodeling (Cancer Research). HPV self-collection raises cervical cancer screening completion by 2.2 pp across 121,000 patients (NEJM Catalyst).

PubMed Top Medical Papers2026/05/26 22:24:25

Five papers worth your time — May 25–26, 2026

VERVE-102 base editing cuts PCSK9 by 88% in Phase 1 (NEJM); four Lancet-family publications round out a quiet two-day window.

PubMed Top Medical Papers2026/05/24 22:27:19

Weekend catch-up — May 24, 2026

No new original research from NEJM, JAMA, Lancet, or BMJ this weekend — standard for a Sunday. Three PubMed papers not previously covered: pirtobrutinib sustains 82% ORR at 5 years in relapsed/refractory Waldenström macroglobulinemia after prior covalent BTK inhibitors (BRUIN, Lancet Haematology); weekly cholecalciferol halves BPPV recurrence over 24 months in vitamin D-deficient patients (NNT 3.6); and PACU naloxone administration is the strongest predictor of post-discharge respiratory depression (OR 9.11, n=95,870).

PubMed Top Medical Papers2026/05/23 22:24:36

Five papers worth your time — May 23, 2026

JAMA leads: protein restriction cuts dialysis risk 35%; trigger bans shift miscarriage care

PubMed Top Medical Papers2026/05/22 22:37:45

Five papers worth your time — May 22, 2026

JAMA Oncology leads with DRAGON-01, a Phase 3 RCT showing intraperitoneal paclitaxel + S-1 extends median OS from 13.9 to 19.4 months (HR 0.67) in gastric cancer with peritoneal metastasis. JAMA publishes Fr1da: universal islet autoantibody screening in 220,476 German children detects 81% of future T1D cases, most with no family history. Also covered: phototherapy duration linked to higher serious morbidity in very preterm neonates (aOR 1.66); GG1 prostate reclassification modeling predicting 2,383 fewer deaths per year; and a recall-based nirsevimab strategy cutting infant bronchiolitis risk by 45–48%.

PubMed Top Medical Papers2026/05/21 22:46:59

Five papers worth your time — May 21, 2026

NEJM published no new original research for a third consecutive day; JAMA family and BMJ lead today's indexing window. Five entries: tocilizumab (IL-6 blocker) reaches 54% remission in biomarker-selected treatment-resistant depression (NNT=5, JAMA Psychiatry proof-of-concept RCT); 69-trial BMJ meta-analysis of 153K patients delivers high-certainty evidence that calcium and vitamin D do not prevent fractures; LOSE-AF finds ~10% weight loss doesn't reduce AF symptoms in older patients; county-level structural racism independently predicts a 34% 2-year lung cancer survival gap (n=54,344); and a Danish registry of 379K individuals reassures that isotretinoin in adolescence is not associated with clinically meaningful height reduction.

PubMed Top Medical Papers2026/05/20 23:14:20

Five papers worth your time — May 20, 2026

No new NEJM original articles in the May 19–20 window — the day's signal came entirely from JAMA and JAMA Network Open. Five entries: 988 Lifeline linked to an 11% decline in youth suicide mortality; INTEGRAL-Risk blood test identifies 85% of 1-year lung cancers vs. 63% by USPSTF criteria; FROSTBITE-2 RCT shows the 1.1-mm cryoprobe outperforms forceps for transbronchial biopsy; the first US placebo-controlled e-cigarette trial shows 3× cessation odds at 6 weeks; and a multicenter NIH-funded cohort finds a 4–8 point IQ differential linked to PICU sedative choice 3–8 years post-discharge.

PubMed Top Medical Papers2026/05/19 22:44:34

Five papers worth your time — May 19, 2026

NEJM and The Lancet dominate the May 19 batch: perioperative pembrolizumab delivers the first Phase 3 EFS win in locally advanced HNSCC; inhaled treprostinil slows FVC decline in IPF across two independent Phase 3 trials (TETON-1/2); SERENA-6 shows camizestrant beats aromatase inhibitor continuation in ESR1-mutant breast cancer — but ODAC voted no on immature OS data; the TOWAR cluster-RCT finds prehospital whole blood equivalent to component therapy for traumatic hemorrhage; and astegolimab (anti-ST2/IL-33) reduces COPD exacerbations regardless of eosinophil count in the ALIENTO/ARNASA trials.

PubMed Top Medical Papers2026/05/18 22:08:10

Five papers worth your time — May 18, 2026

This week's PubMed highlights: ibrutinib secures an OS advantage in MCL and makes ASCT redundant (Lancet TRIANGLE); ensitrelvir cuts household COVID transmission by ~67% in the SCORPIO-PEP trial (NEJM); prophylactic tranexamic acid reduces PPH in placenta praevia caesarean births (BMJ); a single psilocybin dose drives 53% remission in MDD at six weeks (JAMA Network Open); and semaglutide cuts heavy drinking days by 41% in AUD with comorbid obesity (Lancet).